Table 2.

Ongoing clinical trials of IDO1 inhibitors.

Agent	Indications	Identifier	Phase	Strategy	Status	Efficacy
Indoximod (1-D-MT)	Metastatic breast cancer Metastatic glioma Metastatic prostate cancer Melanoma Metastatic pancreatic cancer	NCT01792050 NCT01042535 NCT02052648 NCT01560923 NCT02073123 NCT02077881	II I/II I/II II I/II I/II	Combined with taxane chemotherapy Combined with adenovirus -p53 transduced dendritic cell vaccine Combined with radiation therapy/bevacizumab Combined with sipuleucel-T Combined with Ipilimumab Combined with gemcitabine and nab-paclitaxel	Discontinued Active, not recruiting Recruiting Recruiting Recruiting Recruiting	No major changes were recorded. Unknown Unknown SD = 50% Unknown Unknown
Epacadostat (INCB024360)	Metastatic breast cancer Gastrointestinal stromal tumors Melanoma Fallopian tube cancer, ovarian cancer	NCT02178722 NCT03291054 NCT02752074 NCT02118285	III I/II III I	Combined with pembrolizumab Single agent Combined with pembrolizumab Combined with fludarabine and cyclophosphamide	Active, not recruiting Recruiting Completed Recruiting	No significant changes observed. Unknown No significant differences were found between treatment groups. Unknown
Navoximod (GDC-0919)	Metastatic breast cancer	NCT02048709 NCT02471846	I I	Single agent Combined with atezolizumab	Recruiting Recruiting	No significant differences were found between treatment groups. No significant improvements were recorded compared to atezolizumab therapy alone.

p53: Tumor protein p53; SD: Stable disease.